Identifying subjects suitable for topoisomerase II inhibitor treatment
View Patent ↗The present invention provides methods for diagnosing and treating cancer, and in particular methods for determining the susceptibility of subjects suspected of having breast cancer (or known to have breast cancer) to treatment with topoisomerase II inhibitors. The present invention also provides in situ hybridization probes for specifically detecting topoIIα gene sequences.
1. A method for identifying a candidate for topoisomerase II inhibitor treatment, comprising:
a) providing a sample of breast cancer cells from a candidate subject;
b) detecting a copy number for HER-2/neu and topoIIα in said breast cancer cells; and
c) identifying said candidate subject as suitable for treatment with a topoisomerase II inhibitor, wherein said identifying comprises demonstrating amplification of said copy number for said HER-2/neu and said topoIIα, wherein said amplification indicates said candidate subject is suitable for topoisomerase II inhibitor treatment.
2. The method of claim 1 , wherein said demonstrating comprises comparing said copy number of said HER-2/neu to a control copy number, and comparing said copy number of said topoIIα to said control copy number.
3. The method of claim 2 , wherein said copy number of said HER-2/neu is at least 1.5 times greater than said control copy number.
4. The method of claim 2 , wherein said copy number of said topoIIα is at least 1.5 times greater than said control copy number.
5. The method of claim 1 , wherein said detecting further comprises contacting said sample of breast cancer cells with a first probe specific for said HER-2/neu and a second probe specific for said topoIIα.
6. The method of claim 5 , wherein said second probe comprises at least about 100,000 nucleotides.
7. The method of claim 1 , wherein said detecting comprises in situ hybridization.
8. The method of claim 6 , wherein at least one of said probes is detected by chromogenic in situ hybridization.
9. A method for identifying a candidate for topoisomerase II inhibitor treatment, comprising:
a) providing a sample of breast cancer cells from a candidate subject, wherein said breast cancer cells comprise an amplified copy number for HER-2/neu,
b) detecting a copy number for topoIIα in said breast cancer cells; and
c) identifying said candidate subject as suitable for treatment with a topoisomerase II inhibitor, wherein said identifying comprises demonstrating amplification of said copy number for topoIIα, wherein amplification of both said HER-2/neu and said topoIIα indicates said candidate subject is suitable for topoisomerase II inhibitor treatment.
10. The method of claim 9 , wherein said demonstrating comprises comparing said copy number of said topoIIα to a control copy number.
11. The method of claim 10 , wherein said copy number of said topoIIα is at least 1.5 times greater than said control copy number.